Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1315-1320

  Ieni, A ^a   Giuffre G ^a   Adamo, V ^a   Tuccari, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Breast cancer; CD133; Metastasis; Pre metastatic niche; Prognosis; Stem cells

Indexed keywords

CD133 ANTIGEN; CD34 ANTIBODY; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ARTICLE; BONE; BREAST CARCINOMA; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; COMPARATIVE STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MESODERM; PEPTIDES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 79956127263     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Lawson JC, Blatch GL and Edkins AL: Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat 118: 241-254, 2009.
2. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA and Massagué J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549, 2003.
3. Del Mastro L, Clavarezza M and Venturini M: Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors. Cancer Treat Rev 33: 681-687, 2007. (Pubitemid 350082666)
4. Eccles S, Paon L and Sleeman J: Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 24: 619-636, 2007. (Pubitemid 50001146)
5. Hunter KW, Crawford NP and Alsarraj J: Mechanisms of metastasis. Breast Cancer Res 10(Suppl 1): S2, 2008.
6. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M and Wijelath ES: Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 188: 359-368, 2001.
7. Kaplan RN, Psaila B and Lyden D: Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 25: 521-529, 2006.
8. Geiger TR and Peeper DS: Metastasis mechanisms. Biochim Biophys Acta 1796: 293-308, 2009.
9. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G and Klein CA: Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68, 2008. (Pubitemid 350309740)
10. Pantel K, Brakenhoff RH and Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8: 329-340, 2008. (Pubitemid 351596394)
11. Harris JR, Lippman ME, Morrow M and Hellman S: Diseases of Breast Cancer. Lippincott-Raven, Philadelphia, 1996.
12. Sleeman JP: The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 157: 55-81, 2000.
13. Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19: 3817-3827, 2001. (Pubitemid 32880060)
14. Leong SP: Paradigm shift of staging and treatment for early breast cancer in the sentinel lymph node era. Breast J 12: S128-133, 2006.
15. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S and Lyden D: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827, 2005. (Pubitemid 41753060)
16. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R and Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201, 2001.
17. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T and Shibuya M: Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97: 785-791, 2001. (Pubitemid 32113414)
18. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C and Brambilla E: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188: 369-377, 1999. (Pubitemid 29327434)
19. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC and Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54: 567-572, 1999. (Pubitemid 29407042)
20. Lacal PM, Ruffini F, Pagani E and D'Atri S: An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 27: 1625-1632, 2005.
21. Price DJ, Miralem T, Jiang S, Steinberg R and Avraham H: Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12: 129-135, 2001. (Pubitemid 32677998)
22. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S and Hicklin DJ: The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119: 1519-1529, 2006. (Pubitemid 44258756)
23. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R and Cordon-Cardo C: Expression of c-KIT and KIT ligand proteins in normal human tissues. J Histochem Cytochem 42: 1417-1425, 1994.
24. Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S and Ogawa M: Immunohistochemical expression of the c-KIT proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 73: 1233-1236, 1996. (Pubitemid 26162338)
25. Sperling C, Schwartz S, Büchner T, Thiel E and Ludwig WD: Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica 82: 617-621, 1997. (Pubitemid 28023263)
26. Krystal GW, Hines SJ and Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-KIT and stem cell factor. Cancer Res 56: 370-376, 1996.
27. Ohashi A, Funasaka Y, Ueda M and Ichihashi M: c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Res 6: 25-30, 1996. (Pubitemid 26065018)
28. Hines SJ, Organ C, Kornstein MJ and Krystal GW: Coexpression of the c-KIT and stem cell factor genes in breast carcinomas. Cell Growth Differ 6: 769-779, 1995.
29. Strobl H, Takimoto M, Majdic O, Höcker P and Knapp W: Antigenic analysis of human haemopoietic progenitor cells expressing the growth factor receptor c-KIT. Br J Haematol 82: 287-294, 1992.
30. Baumhueter S, Dybdal N, Kyle C and Lasky LA: Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin. Blood 84: 2554-2565, 1994. (Pubitemid 24317387)
31. + bone marrow progenitors that are expanded by c-KIT-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 182: 1111-1119, 1995.
32. Doyonnas R, Nielsen JS, Chelliah S, Drew E, Hara T, Miyajima A and McNagny KM: Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood 105: 4170-4178, 2005. (Pubitemid 40720759)
33. De Francesco F, Tirino V, Desiderio V, Ferraro G, D'Andrea F, Giuliano M, Libondi G, Pirozzi G, De Rosa A and Papaccio G: Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries. PLoS One 4: 6537, 2009.
34. Nielsen JS and McNagny KM: Novel functions of the CD34 family. J Cell Sci 121: 3683-3692, 2008.
35. Mehra N, Penning M, Maas J, Beerepoot LV, van Daal N, van Gils CH, Giles RH and Voest EE: Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 12: 4859-4866, 2006. (Pubitemid 44338571)
36. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997. (Pubitemid 28007217)
37. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB and Corbeil D: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319: 15-26, 2005. (Pubitemid 40104635)
38. Mizrak D, Brittan M and Alison MR: CD133: molecule of the moment. J Pathol 214: 3-9, 2008.
39. Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H and Sanada Y: CD133 gene overexpression is frequently observed in early colorectal carcinoma. Hepatogastroenterology 56: 995-997, 2009.
40. + tumour cells and clinical outcome in rectal cancer. Histopathology 55: 284-293, 2009.
41. Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, Arima H, Kita Y, Kurahara H, Okumura H, Matsumoto M, Kijima Y and Natsugoe S: Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 30: 2453-2457, 2010.
42. Zhao P, Li Y and Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 10: 218-224, 2010.